ASCO GI 2021 | Infigratinib in previously treated advanced CCA

Ghassan Abou-Alfa, MD, Memorial Sloan-Kettering Cancer Center, New York City, NY, presents the final results from a Phase II study of infigratinib, an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma (CCA) with an FGFR2 gene fusion or rearrangement. Infigratinib is associated with promising anticancer activity and a manageable safety profile in this patient population and a Phase III study is ongoing. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).